104.20
-0.67%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Duality Biotherapeutics
Its shares trade on HKEX under the ticker 9606.HK. It has been listed since 15 April 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.10bn and a net loss of CN¥2.94bn. At that date it held total assets of CN¥4.54bn and shareholders' equity of CN¥2.83bn.
Duality Biotherapeutics Inc is a CN-based company operating in industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-04-15. Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The firm is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The firm's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The firm's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The firm principally conducts its businesses in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 15 Apr 2025
- Employees
- 170
- Website
- dualitybiologics.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Duality Biotherapeutics Inc employs 170 full-time staff in Shanghai to support its operations.
- The company focuses on innovative antibody-drug conjugate therapeutics for cancer and autoimmune diseases.
- Primary drug candidates include DB-1303/BNT323 and DB-1311/BNT324 for targeted treatment of various cancers.
Weaknesses
- The firm is an investment holding company with limited operational diversity beyond biopharmaceuticals.
- Duality Biotherapeutics Inc went public on 15 April 2025, indicating a very recent market entry.
- The company operates in the clinical-stage phase, which carries inherent development risks and uncertainties.
Opportunities
- The firm principally conducts business in domestic and overseas markets to expand its reach.
- Product candidates target endometrial cancer and breast cancer, addressing significant unmet medical needs.
- DB-1419 and DB-2304 offer potential expansion into treating castration-resistant prostate cancer and other indications.
Threats
- Competitive pressure exists in the clinical-stage biopharmaceutical sector for antibody-drug conjugate therapies.
- Regulatory hurdles may delay the approval of drug candidates like DB-1310 and DB-1305/BNT325.
- Market volatility could impact the valuation of Duality Biotherapeutics Inc following its recent IPO.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.